8月25日，贵州百灵（维权）盘中上涨2.12%，截至10:07，报6.27元/股，成交1.07亿元，换手率1.43%， 总市值87.63亿元。 资金流向方面，主力资金净流入437.52万元，特大单买入297.12万元，占比2.78%，卖出562.50万元，占 比5.25%；大单买入2552.71万元，占比23.85%，卖出1849.80万元，占比17.28%。 贵州百灵今年以来股价涨62.86%，近5个交易日涨3.47%，近20日涨16.98%，近60日涨55.20%。 资料显示，贵州百灵企业集团制药股份有限公司位于贵州省安顺市经济技术开发区西航路212号，成立 日期1999年3月25日，上市日期2010年6月3日，公司主营业务涉及以苗药为主的中成药的生产、销售。 主营业务收入构成为：中成药86.97%，西药8.44%，医疗服务2.27%，其他1.91%，中药材0.42%。 贵州百灵所属申万行业为：医药生物-中药Ⅱ-中药Ⅲ。所属概念板块包括：肝炎治疗、抗流感、互联医 疗、中药、创新药等。 截至8月8日，贵州百灵股东户数10.12万，较上期增加18.88%；人均流通股11985股，较上期减少 15.88%。20 ...

从"千年药乡"的历史积淀到"中国药都"核心区的战略部署，甘肃省陇西县依托丰厚的自然禀赋与深厚的 产业根基，借助国家中医药产业发展综合试验区、国家中医药传承创新发展样板区和中国（甘肃）中医 药产业博览会3大平台，叠加大宗地产中药材产地加工、"药食"同源等特殊政策，已构建起种植标准 化、加工精深化、仓储规模化、交易市场化、监测常态化、品牌国际化的全链条发展格局。2024年，全 县中医药全产业链总产值达381亿元，对农民人均可支配收入的贡献率主产区超40%。 从源头筑基筑牢道地药材"车间" "药材好，药才好"。陇西县始终将标准化种植作为产业发展的根基。依托中国药都·陇西药圃园和"国家 药用植物种质资源库甘肃库"两大科研平台，陇西在种子种苗繁育、新品种引进、野生品种驯化等领域 持续发力，制定的黄芪、黄芩、党参等28个标准化种子种苗培育和栽培技术规程，被评审颁布为甘肃省 中药材地方标准，为道地药材品质筑牢"标准防线"。 传统仓储库引入辐照灭菌、低温干燥、红外线干燥、低温充氮等先进技术，全面保障储存环节质量安 全。同时，引进国药集团投资5亿元建设陇西中药材交易仓储中心、康美药业投资15亿元建设西部中药 城、江能医药集团投 ...

Group 1 - The stock price of Jinling Pharmaceutical reached 7.28 yuan as of the close on August 22, 2025, with an increase of 0.02 yuan, representing a rise of 0.28% compared to the previous trading day [1] - The trading volume on that day was 171,300 hands, with a total transaction amount of 125 million yuan [1] - Jinling Pharmaceutical is primarily engaged in the research, development, production, and sales of traditional Chinese medicine, chemical raw materials, and formulations, covering multiple therapeutic areas including cardiovascular, anti-tumor, and digestive systems [1] Group 2 - As of August 20, 2025, the total number of shareholders for Jinling Pharmaceutical was 37,622 [1] - On August 22, the net inflow of main funds was 6.3088 million yuan, with a cumulative net inflow of 18.0238 million yuan over the past five days [1]

Group 1 - The latest stock price of Jilin Aodong is 20.55 yuan, an increase of 0.61 yuan from the previous trading day, with a trading volume of 6.22 billion yuan [1] - Jilin Aodong is primarily engaged in the research, development, manufacturing, and sales of traditional Chinese medicine and biochemical drugs, covering various therapeutic areas including cardiovascular, digestive system, and anti-tumor treatments [1] - On August 22, Jilin Aodong announced that it has returned all 300 million yuan of temporarily idle raised funds to the special account for raised funds [1] Group 2 - On the same day, the net inflow of main funds into Jilin Aodong was 33.96 million yuan, while the net outflow over the past five days was 71.64 million yuan [2]

新天药业主要从事中成药、化学药的研发、生产和销售，产品涵盖感冒药、心脑血管用药等多个领域。 公司所属行业为医药制造业，涉及中药、流感等概念板块。 风险提示：股市有风险，投资需谨慎。 截至2025年8月22日收盘，新天药业股价报12.55元，较前一交易日下跌2.18%。当日股价波动明显，开 盘报13.00元，最高触及13.29元，最低下探12.49元，振幅达6.24%。盘中曾出现快速反弹，10点04分时5 分钟内涨幅超过2%，成交金额达1.82亿元。 从资金流向来看，8月22日主力资金净流出513.17万元，近五日累计净流出324.83万元。当日换手率为 14.66%，成交量为34.99万手，成交金额达4.48亿元。 ...

截至2025年8月21日收盘，天目药业股价报17.50元，较前一交易日下跌1.08元。当日开盘价为19.06元， 最高触及20.44元，最低下探至17.36元，全天振幅达16.58%。成交量为21.65万手，成交金额4.09亿元。 天目药业主要从事中成药、化学药制剂、生物制品等医药产品的研发、生产和销售。公司产品涵盖心脑 血管、抗肿瘤、抗感染等多个治疗领域。 8月21日盘中，天目药业股价出现快速波动。上午9点39分出现快速反弹，5分钟内涨幅超过2%；但在早 盘9点35分也曾出现快速回调，5分钟内跌幅超过2%。 资金流向方面，8月21日主力资金净流出5072.56万元，占流通市值的2.38%。近五个交易日累计净流出 2391.73万元，占流通市值的1.12%。 风险提示：股市有风险，投资需谨慎。 ...

Group 1 - The stock price of Taiji Group is reported at 23.21 yuan, down 0.25 yuan or 1.07% from the previous trading day, with a trading volume of 136,551 hands and a transaction amount of 319 million yuan [1] - Taiji Group is primarily engaged in the research, development, production, and sales of traditional Chinese medicine, chemical drugs, and biopharmaceuticals, covering various therapeutic areas including digestive, respiratory, cardiovascular, and anti-infection [1] - The company disclosed its semi-annual report for 2025, showing a revenue of 5.658 billion yuan, a year-on-year decrease of 27.63%, and a net profit attributable to shareholders of 139 million yuan, down 71.94% year-on-year, mainly due to policy impacts and inventory digestion of certain products [1] Group 2 - The company announced plans to publicly transfer a vacant property in Chengdu with an assessed value of 39.136 million yuan [1] - In terms of capital flow, Taiji Group experienced a net outflow of 30.6396 million yuan on the day, with a cumulative net outflow of 237.7444 million yuan over the past five days [1]

Company Overview - Zhongsheng Pharmaceutical closed at 22.79 yuan on August 20, down 1.04 yuan, a decrease of 4.36% from the previous trading day [1] - The opening price was 23.39 yuan, with a high of 24.34 yuan and a low of 22.50 yuan, and the trading volume reached 661,194 hands with a transaction amount of 1.537 billion yuan [1] Business Operations - Zhongsheng Pharmaceutical is primarily engaged in the manufacturing of pharmaceuticals, focusing on the research, production, and sales of traditional Chinese medicine, chemical drugs, and biological drugs [1] - The company's product range covers multiple therapeutic areas, including cardiovascular, anti-infection, digestive system, and respiratory system [1] Market Activity - On the morning of August 20, Zhongsheng Pharmaceutical experienced a rapid rebound, with a rise of over 2% within 5 minutes, peaking at 24.01 yuan [1] - The net outflow of main funds on that day was 120.6993 million yuan, while the net inflow over the past five days was 14.899 million yuan [1]

益佰制药发布公告称，拟以8000万元受让控股子公司益佰中药配方颗粒制药有限公司40.03%的股权， 交易完成后将持有该公司100%股权。公司2025年半年报显示，上半年实现营业收入9.93亿元，同比下 降15.0%；归母净利润亏损1990万元，较去年同期亏损1.06亿元有所收窄。 益佰制药股价报4.55元，较前一交易日下跌0.87%。开盘价为4.66元，盘中最高触及4.75元，最低下探 4.47元，成交量为1121773手，成交金额达5.18亿元。 风险提示：股市有风险，投资需谨慎。 该公司主营业务为医药工业、医疗服务和大健康产业。医药工业板块主要产品包括化学药、中成药和生 物药，涉及肿瘤、心脑血管、妇科等多个治疗领域。医疗服务板块运营综合性医院和肿瘤专科医院，大 健康产业板块则开发以苗药为特色的健康产品。 来源：金融界 ...

Group 1 - The core viewpoint of the article highlights the decline in the production of traditional Chinese medicine (TCM) in China, with a projected decrease in output and significant year-on-year reductions [1][3] - According to data from the National Bureau of Statistics, the production of TCM in China is expected to be 156,000 tons by June 2025, representing a year-on-year decrease of 6.6% [1] - In the first half of 2025, the cumulative production of TCM in China reached 875,000 tons, showing a cumulative decline of 13% [1] Group 2 - The article lists several publicly listed companies in the TCM sector, including Yunnan Baiyao, Tongrentang, and others, indicating the key players in the industry [1] - The report referenced is the "2025-2031 China Traditional Chinese Medicine Industry Development Situation Analysis and Industry Prospect Planning Report" published by Zhiyan Consulting, which provides insights into the future of the TCM industry [1][2]